The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Gwang Sil Kim (Kim GS), Joong Hyun Park (Park JH), Jong Chul Won (Won JC)
Endocrinol Metab. 2019;34(2):106-116.   Published online 2019 May 9     DOI:
Citations to this article as recorded by Crossref logo
Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction
Yan Liu, Zhenzhen Chen, Lei Liu, Haitao Tang, Huaqing Zhu, Songtao Tang
Cellular Signalling.2022; 90: 110193.     CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171.     CrossRef
Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
Jung Ha Park, Ju Young Kim, Jong Han Choi, Hye Soon Park, Hyun-Young Shin, Jae Min Lee, Jin-Wook Kim, Hae-Jin Ko, Suk Chon, Bu Kyung Kim, Chul Sik Kim, Soo Lim
International Journal of Obesity.2021; 45(4): 776.     CrossRef
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh
Heart.2021; 107(13): 1032.     CrossRef
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
Cardiovascular Diabetology.2020;[Epub]     CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
Drug Safety.2019; 42(11): 1311.     CrossRef